NCT03489200View on ClinicalTrials.gov

EH301 for the Treatment of ALS

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Amyotrophic Lateral Sclerosis
Interventions
OTHER

EH301

1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene

OTHER

Placebo

No intervention- placebo

Trial Locations (1)

Unknown

Universidad Católica de Valencia San Vicente Màrtir, Valencia

Sponsors

Lead Sponsor

Elysium Health
All Listed Sponsors
collaborator

Fundación Universidad Católica de Valencia San Vicente Mártir

OTHER

collaborator

University of Valencia

OTHER

lead

Elysium Health

INDUSTRY

NCT03489200 - EH301 for the Treatment of ALS | Biotech Hunter | Biotech Hunter